+++ Konso abgeschlossen - es darf wieder +++ - 500 Beiträge pro Seite
eröffnet am 01.12.03 18:02:16 von
neuester Beitrag 02.12.03 09:41:34 von
neuester Beitrag 02.12.03 09:41:34 von
Beiträge: 13
ID: 800.640
ID: 800.640
Aufrufe heute: 0
Gesamt: 399
Gesamt: 399
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 27 Minuten | 9707 | |
| vor 42 Minuten | 6309 | |
| vor 28 Minuten | 3192 | |
| vor 28 Minuten | 3135 | |
| vor 20 Minuten | 3116 | |
| vor 28 Minuten | 2897 | |
| vor 54 Minuten | 2375 | |
| vor 42 Minuten | 2343 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.906,40 | -1,01 | 237 | |||
| 2. | 3. | 163,25 | +0,69 | 87 | |||
| 3. | 4. | 0,1905 | -1,80 | 85 | |||
| 4. | 2. | 9,2650 | -3,94 | 83 | |||
| 5. | 34. | 0,6450 | -53,93 | 62 | |||
| 6. | 6. | 0,0262 | +24,17 | 59 | |||
| 7. | 14. | 6,9820 | +3,62 | 56 | |||
| 8. | 13. | 435,48 | -11,76 | 47 |
Feedback
gekauft werden
Nach den letzten News
dürfte es wohl nach der letzten Konsolidierung weiter mit dramatischen Kursgewinnen zu rechnen sein
Wir stehen exakt an der 200 Tagelinie und die wird nicht mehr nach unten durchbrochen werden
D.h. es können erste Positionen aufgebaut werden
Hier die letzten News für diejenigen, die sie noch nicht kenne. Es steckt unglaublich Pantasie in dem Wert
LAM Pharmaceutical and Ixora Bio Medical Announce The Launch of Ixora`s First Product
Tuesday November 25, 7:02 am ET
LEWISTON, N.Y., Nov. 25 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that Ixora Bio Medical Company Inc., a licensee of LAM, is poised to commence marketing and commercial sales of " Ixora(TM) for Women" , a non-prescription female sexual enhancement product Ixora has licensed from LAM.
ADVERTISEMENT
John Easton, Chief Executive Officer of Ixora Bio Medical, stated, " The impending launch of `Ixora(TM) for Women` represents a major milestone for us. It is the culmination of four years of extensive research and development, clinical studies and marketing research. `Ixora(TM) for Women` is the first of several products addressing sexual dysfunction in both men and women based on LAM IPM Ionic Polymer Matrix platform that Ixora has licensed from LAM. It will be marketed and sold as a sophisticated, upscale sexual enhancement product, addressing the difficulties associated with female sexual function disorders. The Journal of the American Medical Association has stated that 43.0% of American women have faced at least one sexual function issue. These statistics are based on a national sampling of women ages 18-59."
Mr. Easton added, " In preparation for the launch, Ixora has assembled a group of first class professionals including a medical advisory board as well as branding, marketing and public relations teams. Ixora Bio Medical has established a network of sales outlets throughout North America for its `Ixora(TM) for Women` and has contracted manufacturing to a leading New Jersey based FDA approved GMP manufacturing facility."
Joseph Slechta, President and Chief Executive Officer of LAM, remarked, " We are very pleased about our licensee`s achievement. Ixora has had our total support throughout the commercialization stage. We will work with Ixora`s marketing team to ensure the successful launch of its first product. LAM anticipates royalty revenues from `Ixora(TM) for Women` to commence in the first half of 2004."
Mr. Slechta concluded, " The upcoming launch of `Ixora(TM) for Women` is particularly timely. The subject of human sexuality has come to the forefront in recent years and we are proud that Ixora has the opportunity to make a major positive contribution to this field."
About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.
About Ixora Bio Medical Company Inc.
Ixora Bio Medical Company is a biomedical company with headquarters in New York City. Ixora holds a world wide exclusive license from LAM for sexual dysfunction products based on LAM`s patented proprietary IPM Ionic Polymer Matrix transdermal delivery platform. The Company`s current focus is to develop and commercialize sexual enhancement products. More information about Ixora can be obtained by visiting www.Ixoraforwomen.com.
Statements in this press release regarding our business which are not historical facts are " forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Nach den letzten News
dürfte es wohl nach der letzten Konsolidierung weiter mit dramatischen Kursgewinnen zu rechnen sein
Wir stehen exakt an der 200 Tagelinie und die wird nicht mehr nach unten durchbrochen werden
D.h. es können erste Positionen aufgebaut werden
Hier die letzten News für diejenigen, die sie noch nicht kenne. Es steckt unglaublich Pantasie in dem Wert
LAM Pharmaceutical and Ixora Bio Medical Announce The Launch of Ixora`s First Product
Tuesday November 25, 7:02 am ET
LEWISTON, N.Y., Nov. 25 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that Ixora Bio Medical Company Inc., a licensee of LAM, is poised to commence marketing and commercial sales of " Ixora(TM) for Women" , a non-prescription female sexual enhancement product Ixora has licensed from LAM.
ADVERTISEMENT
John Easton, Chief Executive Officer of Ixora Bio Medical, stated, " The impending launch of `Ixora(TM) for Women` represents a major milestone for us. It is the culmination of four years of extensive research and development, clinical studies and marketing research. `Ixora(TM) for Women` is the first of several products addressing sexual dysfunction in both men and women based on LAM IPM Ionic Polymer Matrix platform that Ixora has licensed from LAM. It will be marketed and sold as a sophisticated, upscale sexual enhancement product, addressing the difficulties associated with female sexual function disorders. The Journal of the American Medical Association has stated that 43.0% of American women have faced at least one sexual function issue. These statistics are based on a national sampling of women ages 18-59."
Mr. Easton added, " In preparation for the launch, Ixora has assembled a group of first class professionals including a medical advisory board as well as branding, marketing and public relations teams. Ixora Bio Medical has established a network of sales outlets throughout North America for its `Ixora(TM) for Women` and has contracted manufacturing to a leading New Jersey based FDA approved GMP manufacturing facility."
Joseph Slechta, President and Chief Executive Officer of LAM, remarked, " We are very pleased about our licensee`s achievement. Ixora has had our total support throughout the commercialization stage. We will work with Ixora`s marketing team to ensure the successful launch of its first product. LAM anticipates royalty revenues from `Ixora(TM) for Women` to commence in the first half of 2004."
Mr. Slechta concluded, " The upcoming launch of `Ixora(TM) for Women` is particularly timely. The subject of human sexuality has come to the forefront in recent years and we are proud that Ixora has the opportunity to make a major positive contribution to this field."
About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.
About Ixora Bio Medical Company Inc.
Ixora Bio Medical Company is a biomedical company with headquarters in New York City. Ixora holds a world wide exclusive license from LAM for sexual dysfunction products based on LAM`s patented proprietary IPM Ionic Polymer Matrix transdermal delivery platform. The Company`s current focus is to develop and commercialize sexual enhancement products. More information about Ixora can be obtained by visiting www.Ixoraforwomen.com.
Statements in this press release regarding our business which are not historical facts are " forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Vielleicht kann mal jemand den WO-Linienchart einstellen - wäre nett
Habs immer noch nicht begriffen
Habs immer noch nicht begriffen
Jawoll Engel Gabriel,
so wird das laufen - und nicht anders!
Die Produkte, das Management, die kommenden Umsätze nebst vielversprechender Lizenzverträge und nicht zu vergessen das fleißige Bienchen in Luxemburg, werden dieser Aktie zu einem Hype verhelfen, der sich gewaschen hat! Wie in alten Goldgräberzeiten!
Holt schon mal eure Schubkarren aus den Gartenhäusern, damit ihr die Gewinne einfahren könnt!
Gutes Gelingen,
DIE PÄPSTIN
so wird das laufen - und nicht anders!
Die Produkte, das Management, die kommenden Umsätze nebst vielversprechender Lizenzverträge und nicht zu vergessen das fleißige Bienchen in Luxemburg, werden dieser Aktie zu einem Hype verhelfen, der sich gewaschen hat! Wie in alten Goldgräberzeiten!
Holt schon mal eure Schubkarren aus den Gartenhäusern, damit ihr die Gewinne einfahren könnt!
Gutes Gelingen,
DIE PÄPSTIN
Seht Ihr den kleinen Zacken unten rechts. Der wird ausbrechen und über das letzte Hoch hinausrauschen
Sehr schöner Chart. Vielleicht auch den Chart von der OTC, da dort der Kurs gemacht wird. Da stehen wir exakt an der 200 Tagelinie
Sehr schöner Chart. Vielleicht auch den Chart von der OTC, da dort der Kurs gemacht wird. Da stehen wir exakt an der 200 Tagelinie
Trading Spotlight
JJaaaaaaaaaaaaaaaaaaaaaaaah!
Nur wann?
Päpstin
Nur wann?
Päpstin
In 20 Minuten gerade mal 120 mal gelesen
Das ändert sich auch wieder bei Lamp
Dann rennt halt später alle wieder hinterher.
Das ändert sich auch wieder bei Lamp
Dann rennt halt später alle wieder hinterher.
Post allerwerteste Himmelsbotschafterin
na, bevor der kurs abrauscht, hab ich nochmal zu gelangt fra auf 0,16
fra auf 0,16
@McGabriel
Sag mal Maccie, über die 0,20 muß es aber schon noch gehen, bevor wir von einem Ausbruch sprechen können oder?
GN
Sag mal Maccie, über die 0,20 muß es aber schon noch gehen, bevor wir von einem Ausbruch sprechen können oder?
GN
Klar Günther muß und wird es auch über die 0.20 gehen.
Es kann nicht immer so schnell gehen. Manchmal braucht man etwas Geduld
Es kann nicht immer so schnell gehen. Manchmal braucht man etwas Geduld
Ehhh MC Gabe,
und sprich mich niieeeeeee wieder mit "allerwerteste ..." an, dann bekommst du einen Tritt in Selbigen!
Päpstin
und sprich mich niieeeeeee wieder mit "allerwerteste ..." an, dann bekommst du einen Tritt in Selbigen!
Päpstin
@McGabriel
Ich würde sagen, das gestrige Volumen gibt uns ernsthafte Hinweise, daß Du recht haben könntest...
GN
Ich würde sagen, das gestrige Volumen gibt uns ernsthafte Hinweise, daß Du recht haben könntest...
GN
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 90 | ||
| 86 | ||
| 86 | ||
| 60 | ||
| 55 | ||
| 53 | ||
| 47 | ||
| 41 | ||
| 33 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 32 | ||
| 29 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 26 | ||
| 24 | ||
| 24 | ||
| 22 |
